Arc Bio, which has a presence in Menlo Park, Calif., and Cambridge, Mass., has unveiled its Galileo antimicrobial resistance (AMR) detection software, which aims to identify and annotate any gram-negative bacterial DNA sequence in less than five minutes.

Boston Scientific Corp., of Marlborough, Mass., agreed to acquire Claret Medical Inc., the developer of the Sentinel cerebral embolic protection system, for $220 million in up-front cash, as well as a potential reimbursement-based milestone payment of up to $50 million.

Washington-based Danaher Corp. (NYSE:DHR) was on the rise Thursday following news that it planned to spin off its dental business into a separate company. The company reported the plans the same day as its second-quarter earnings call. Danaher ended Wednesday at $98.78, but closed at $103.20 Thursday.

Stryker Corp., of Kalamazoo, Mich., won FDA approval for the Surpass Streamline flow diverter to treat unruptured large and giant wide neck intracranial aneurysms. It is the second flow diverting stent to gain a green light in the U.S.